Centella Mauritius Holdings, backed by TPG, is divesting a 7.2% stake in Aster DM Quality Care through a block deal valued at ₹4,780 crore. The shares are offered at a floor price of ₹766.10, representing a discount to the recent market price. Investors are watching this move as the company works to improve margins following a significant decline in recent quarterly profits.
Centella Mauritius Holdings Ltd, an investment vehicle linked to TPG Inc., has initiated a sale of a 7.2% equity stake in Aster DM Quality Care Ltd. The transaction is structured as a block deal and is valued at approximately ₹4,780 crore, or $575 million. The deal has been set with a floor price of ₹766.10 per share, which marks a discount of roughly 6.3% compared to the stock's previous closing price on the National Stock Exchange.
The stake sale comes after the significant corporate restructuring that merged Aster DM Healthcare with Quality Care India Limited, resulting in the current entity. On the day of the announcement, August 18, 2026, shares of Aster DM Quality Care Ltd closed at ₹819.20 on the BSE, recording a marginal decline of 0.049%. Following this transaction, the selling entity will be subject to a 60-day lock-in period, during which it cannot offload any further shares, providing some short-term certainty regarding the promoter group's holding.
While the block deal provides liquidity for the investor, the broader financial context remains a point of focus for current shareholders. In the first quarter of fiscal year 2027, the company reported a sharp 81% year-on-year drop in net income, which fell to ₹160.6 million. Profit margins also saw a contraction, dropping to 1.2% from 7.9% in the same quarter last year. These figures suggest that the business is facing operational pressure, possibly from the integration of the merged assets or higher costs.
Governance and board stability are also areas that some investors track. The company has seen a high turnover of board members, with seven new directors appointed over the last three years. Such changes are often monitored by market participants for signs of management stability and strategic continuity.
Looking ahead, the company's valuation and stock performance will likely hinge on its expansion progress. The management has set a target to add 1,700 beds by fiscal year 2027. The key monitorable for investors will be whether the company can successfully ramp up its new capacity while simultaneously reversing the recent trend of shrinking profit margins. Future quarterly results and management commentary on cost control will be essential for gauging the company’s path back to higher profitability.